| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
marketing1@energy-chemical.com |
|
| | PF-06761281 Basic information |
| Product Name: | PF-06761281 | | Synonyms: | PF-06761281;PF-06761281 >=97% (HPLC);Butanedioic acid, 2-hydroxy-2-[2-(2-methoxy-5-methyl-3-pyridinyl)ethyl]-, (2R)- | | CAS: | 1854061-19-0 | | MF: | C13H17NO6 | | MW: | 283.28 | | EINECS: | | | Product Categories: | | | Mol File: | 1854061-19-0.mol |  |
| | PF-06761281 Chemical Properties |
| Boiling point | 469.7±45.0 °C(Predicted) | | density | 1.358±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | H2O: 20 mg/mL, clear | | pka | 3.37±0.28(Predicted) | | form | powder | | color | white to beige | | Water Solubility | H2O: 20mg/mL, clear | | InChI | 1S/C13H17NO6/c1-8-5-9(11(20-2)14-7-8)3-4-13(19,12(17)18)6-10(15)16/h5,7,19H,3-4,6H2,1-2H3,(H,15,16)(H,17,18)/t13-/m1/s1 | | InChIKey | FGYMJXFSHBLHLW-CYBMUJFWSA-N | | SMILES | CC1=CC(CC[C@](CC(O)=O)(O)C(O)=O)=C(OC)N=C1 |
| RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | WGK 3 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral |
| | PF-06761281 Usage And Synthesis |
| Uses | PF-06761281 has been used as a SLC13A family inhibitor, in rats to determine its unbound partition coefficient (Kpuu), to estimate its potency as a drug. | | General Description | PF-06761281 is a small, polar dicarboxylate compound. Its structure is similar to citrate, which is the endogenous substrate of Na+-citrate cotransporter (NaCT). It is a novel, potent inhibitor of SLC13a2/3/5 (solute channel) family, along with selectivity for NaCT. | | Biochem/physiol Actions | PF-06761281 is an inhibitor of the sodium-coupled citrate transporter (NaCT or SLC13A5), which may be a target for tretment and prevention of metabolic disorders. The SLC13 transporters SLC13A2 (NaDC1), SLC13A3 (NaDC3), and SLC13A5 (NaCT) co-transport di- and tricarboxylates with multiple sodium ions into cells. PF-06761281 inhibits citrate uptake with an IC50 of 740 nM for NaCT in human hepatocytes. PF-06761281 has >25-fold in vitro selectivity for NaCT over NaDC1 and NaDC3 and was inactive in a selectivity panel of 65 targets. |
| | PF-06761281 Preparation Products And Raw materials |
|